METHOD OF PREDICTION OF THE RESPONSE TO THE TREATMENT OF MULTIPLE SCLEROSIS WITH BETA INTERFERON

Description

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system. In recent years, numerous drugs have been developed to alleviate the effects of this disease, where interferon beta (IFNß) continues to be one of the first-line treatments, validated and implemented in clinical practice due to its efficacy and safety profile. However, a percentage of 30-50% of patients do not respond adequately to IFNß treatment. This is why there is a need for biomarkers that predict whether an MS patient will respond adequately to said treatment. For this reason, the researchers propose the determination of a biomarker in a biological sample isolated from the patient with a technique developed in the laboratory that allows it to be predicted. Likewise, the development of an ELISA kit or device has also been suggested, which includes the elements necessary to quantify said levels and thus predict or predict the response of an individual with multiple sclerosis to treatment with IFNß.

Advantages

This new forecasting method has the following advantages: - It allows predicting whether or not a patient with MS will respond to treatment with IFNß. - The test is performed in serum, a method that is minimally invasive for the patient. - Easy to implement since the ELISA technique is a common tool used in clinical laboratories.

Uses and Applications

Of use and application in the field of Health Sciences. Specifically, in the field of methods of prediction or prognosis of response to treatment with IFNß in multiple sclerosis disease.